Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma
- PMID: 22532250
- DOI: 10.1093/carcin/bgs154
Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma
Abstract
DNA methylation affects the aggressiveness of human malignancies. Cancers with CpG island methylator phenotype (CIMP), a distinct group with extensive DNA methylation, show characteristic features in several types of tumors. In this study, we initially defined the existence of CIMP in 41 lung adenocarcinomas (AdCas) through genome-wide DNA methylation microarray analysis. DNA methylation status of six CIMP markers newly identified by microarray analysis was further estimated in a total of 128 AdCas by bisulfite pyrosequencing analysis, which revealed that 10 (7.8%), 40 (31.3%) and 78 (60.9%) cases were classified as CIMP-high (CIMP-H), CIMP-low and CIMP-negative (CIMP-N), respectively. Notably, CIMP-H AdCas were strongly associated with wild-type epidermal growth factor receptor (EGFR), males and heavy smokers (P = 0.0089, P = 0.0047 and P = 0.0036, respectively). In addition, CIMP-H was significantly associated with worse prognosis; especially among male smokers, CIMP-H was an independent prognostic factor (hazard ratio 1.7617, 95% confidence interval 1.0030-2.9550, P = 0.0489). Compellingly, the existence of CIMP in AdCas was supported by the available public datasets, such as data from the Cancer Genome Atlas. Intriguingly, analysis of AdCa cell lines revealed that CIMP-positive AdCa cell lines were more sensitive to a DNA methylation inhibitor than CIMP-N ones regardless of EGFR mutation status. Our data demonstrate that CIMP in AdCas appears to be a unique subgroup that has distinct clinical traits from other AdCas. CIMP classification using our six-marker panel has implications for personalized medical strategies for lung cancer patients; in particular, DNA methylation inhibitor might be of therapeutic benefit to patients with CIMP-positive tumors.
Similar articles
-
Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus.Cancer. 2006 Apr 1;106(7):1467-79. doi: 10.1002/cncr.21789. Cancer. 2006. PMID: 16518809
-
CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus.Clin Cancer Res. 2006 May 15;12(10):2995-3002. doi: 10.1158/1078-0432.CCR-05-1601. Clin Cancer Res. 2006. PMID: 16707594
-
Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma.Tumour Biol. 2016 Aug;37(8):10675-84. doi: 10.1007/s13277-016-4932-2. Epub 2016 Feb 11. Tumour Biol. 2016. PMID: 26867769
-
CpG island methylator phenotype (CIMP) in cancer: causes and implications.Cancer Lett. 2008 Sep 18;268(2):177-86. doi: 10.1016/j.canlet.2008.03.022. Epub 2008 May 8. Cancer Lett. 2008. PMID: 18471961 Review.
-
Biological significance of the CpG island methylator phenotype.Biochem Biophys Res Commun. 2014 Dec 5;455(1-2):35-42. doi: 10.1016/j.bbrc.2014.07.007. Epub 2014 Jul 10. Biochem Biophys Res Commun. 2014. PMID: 25016183 Review.
Cited by
-
Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma.Virchows Arch. 2015 Jun;466(6):675-83. doi: 10.1007/s00428-015-1749-0. Epub 2015 Mar 13. Virchows Arch. 2015. PMID: 25772390
-
Differential gene expression analysis of HNSCC tumors deciphered tobacco dependent and independent molecular signatures.Oncotarget. 2019 Oct 22;10(58):6168-6183. doi: 10.18632/oncotarget.27249. eCollection 2019 Oct 22. Oncotarget. 2019. PMID: 31692905 Free PMC article.
-
Systems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinoma.BMC Syst Biol. 2013 Dec 26;7:141. doi: 10.1186/1752-0509-7-141. BMC Syst Biol. 2013. PMID: 24369052 Free PMC article.
-
Comprehensive molecular profiling of lung adenocarcinoma.Nature. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9. Nature. 2014. PMID: 25079552 Free PMC article.
-
Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.Mol Oncol. 2016 Feb;10(2):330-43. doi: 10.1016/j.molonc.2015.10.021. Epub 2015 Nov 6. Mol Oncol. 2016. PMID: 26601720 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous